Graft versus tumor effects and why people relapse
- 8 December 2017
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2017 (1) , 693-698
Abstract
Graft-versus-tumor (GVT) reactivity mediated by donor T cells in the context of allogeneic stem cell transplantation (alloSCT) is one of the most potent forms of cellular immunotherapy. The antitumor effect against hematologic malignancies is mediated by a polyclonal T-cell response targeting polymorphic antigens expressed on hematopoietic tissues of the recipient, leaving donor hematopoiesis in the patient after transplantation unharmed. Fortunately, hematopoietic tissues (including malignant hematopoietic cell populations) are relatively susceptible to T-cell recognition. If, however, nonhematopoietic tissues of the recipient are targeted as well, graft-versus-host disease (GVHD) will occur. The balance between GVT and GVHD is influenced by the genetic disparity between donor and recipient, the number and origin of professional antigen-presenting cells provoking the immune response, the target antigen specificity, magnitude and diversity of the response, and the in vivo inflammatory environment, whereas inhibitory factors may silence the immune response. Manipulation of each of these factors will determine the balance between GVT and GVHD.Keywords
This publication has 36 references indexed in Scilit:
- Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant PatientsScience Translational Medicine, 2013
- Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot studyHaematologica, 2012
- Alloreactivity Across HLA Barriers Is Mediated by Both Naïve and Antigen-Experienced T CellsTransplantation and Cellular Therapy, 2011
- Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cellsBlood, 2010
- Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigensBlood, 2010
- NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia ReactionTransplantation and Cellular Therapy, 2010
- Allo-HLA reactivity of virus-specific memory T cells is commonBlood, 2010
- Loss of Mismatched HLA in Leukemia after Stem-Cell TransplantationNew England Journal of Medicine, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- Positive and Negative Selection of T CellsAnnual Review of Immunology, 2003